Zacks Investment Research upgraded shares of Arcturus Therapeutics (NASDAQ:ARCT) from a sell rating to a hold rating in a research note published on Monday.

According to Zacks, “Arcturus Therapeutics Ltd. is a preclinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of RNA medicines using proprietary lipid-mediated delivery system LUNAR(TM) and UNA Oligomer chemistry technologies. Arcturus Therapeutics Ltd, formerly known as Alcobra Ltd, is based in San Diego, CA. “

Several other analysts have also recently issued reports on the company. Laidlaw started coverage on Arcturus Therapeutics in a research note on Tuesday, February 19th. They set a buy rating on the stock. Roth Capital restated a buy rating on shares of Arcturus Therapeutics in a research note on Wednesday, February 20th. Finally, ValuEngine cut Arcturus Therapeutics from a buy rating to a hold rating in a research note on Friday, December 21st. Two investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. The stock presently has a consensus rating of Buy and a consensus target price of $11.63.

Shares of NASDAQ ARCT opened at $5.40 on Monday. Arcturus Therapeutics has a 52-week low of $4.11 and a 52-week high of $10.00. The company has a current ratio of 3.33, a quick ratio of 2.53 and a debt-to-equity ratio of 0.73.

Arcturus Therapeutics (NASDAQ:ARCT) last announced its quarterly earnings data on Monday, March 18th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.51) by $0.41. The firm had revenue of $7.58 million for the quarter, compared to analyst estimates of $3.59 million. Sell-side analysts expect that Arcturus Therapeutics will post -1.96 earnings per share for the current year.

Several institutional investors have recently made changes to their positions in ARCT. BlackRock Inc. acquired a new stake in shares of Arcturus Therapeutics during the 2nd quarter worth approximately $169,000. JPMorgan Chase & Co. raised its position in shares of Arcturus Therapeutics by 91.7% during the 3rd quarter. JPMorgan Chase & Co. now owns 16,744 shares of the biotechnology company’s stock worth $148,000 after purchasing an additional 8,008 shares during the period. Finally, Worth Venture Partners LLC acquired a new stake in shares of Arcturus Therapeutics during the 3rd quarter worth approximately $290,000. Institutional investors and hedge funds own 10.88% of the company’s stock.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Ltd., an RNA medicines company, develops nucleic acid medicines to treat diseases with unmet medical needs. Its RNA therapeutics platforms could be applied in various types of RNA medicines, including small interfering RNA, messenger RNA, replicon RNA, antisense RNA, microRNA, and gene editing therapeutics.

Featured Story: Economic Reports

Get a free copy of the Zacks research report on Arcturus Therapeutics (ARCT)

For more information about research offerings from Zacks Investment Research, visit

Analyst Recommendations for Arcturus Therapeutics (NASDAQ:ARCT)

Receive News & Ratings for Arcturus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcturus Therapeutics and related companies with's FREE daily email newsletter.